Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma

BACKGROUND: Multiple myeloma (MM) remains incurable despite recent therapeutic advances. RAS mutations are frequently associated with relapsed/refractory disease. Efforts to target the mitogen-activated protein kinase (MAPK) pathway with the MEK inhibitor, trametinib (Tra) have been limited by toxic...

Descripción completa

Detalles Bibliográficos
Autores principales: Sriskandarajah, Priya, De Haven Brandon, Alexis, MacLeod, Kenneth, Carragher, Neil O., Kirkin, Vladimir, Kaiser, Martin, Whittaker, Steven R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106683/
https://www.ncbi.nlm.nih.gov/pubmed/32228485
http://dx.doi.org/10.1186/s12885-020-06735-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7106683/
https://www.ncbi.nlm.nih.gov/pubmed/32228485
http://dx.doi.org/10.1186/s12885-020-06735-2

Ejemplares similares